Abstract:Objectives This prospective cohort study tested for associations between baseline cognitive performance in individuals early within their first episode and antipsychotic treatment of psychosis. We hypothesised that poorer cognitive functioning at the initial assessment would be associated with poorer antipsychotic response following the subsequent 6 weeks. Design Prospective cohort . Setting National Health Service users with a first-episode schizophrenia diagnosis, recently starting antipsychotic medication, recruited from two UK sites (King's College London, UK and University of Manchester, UK). Participants attended three study visits following screening. Participants Eighty-nine participants were recruited, with 46 included in the main analysis. Participants required to be within the first 2 years of illness onset, had received minimal antipsychotic treatment, have the capacity to provide consent, and be able to read and write in English. Participants were excluded if they met remission criteria or showed mild to no symptoms. Primary and secondary outcome measures Antipsychotic response was determined at 6 weeks using the Positive and Negative Syndrome Scale (PANSS), with cognitive performance assessed at each visit using the Brief Assessment of Cognition in Schizophrenia (BACS). The groups identified (responders and non-responders) from trajectory analyses, as well as from >20% PANSS criteria, were compared on baseline BACS performance. Results Trajectory analyses identified 84.78% of the sample as treatment responsive, and the remaining 15.22% as treatment non-responsive. Unadjusted and adjusted logistic regressions observed no significant relationship between baseline BACS on subscale and total performance (BACS t-score: OR=0.98, p=0.620, Cohen's d=0.218) and antipsychotic response at 6 weeks. Conclusions This investigation identified two clear trajectories of treatment response in the first 6 weeks of antipsychotic treatment. Responder and non-responder groups did not significantly differ on performance on the BACS, suggesting that larger samples may be required or that an association between cognitive performance and antipsychotic response is not observable in the first 2 years of illness onset. Trial registration number REC: 17/NI/0209.

Incidence and factors associated of early non-response in first-treatment and drug-naïve patients with schizophrenia: a real-world study

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Gut Microbial Biomarkers for the Treatment Response in First-Episode, Drug-Naïve Schizophrenia: a 24-Week Follow-Up Study

Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial

Association of Telomere Length and Mitochondrial DNA Copy Number with Risperidone Treatment Response in First-Episode Antipsychotic-Naïve Schizophrenia

Predictors of Response to Second Generation Antipsychotics in Drug Naïve Patients with Schizophrenia: A 1 Year Follow-Up Study in Shanghai

Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study

Prediction of Early Response to Overall Treatment for Schizophrenia: A Functional Magnetic Resonance Imaging Study.

Relationship between efficacy and common metabolic parameters in first-treatment drug-naïve patients with early non-response schizophrenia: a retrospective study

Stratification and prediction of remission in first-episode psychosis patients OPTIMISE

Short-term antipsychotic treatment response in early-onset, typical-onset, and late-onset first episode schizophrenia

Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis

Neurodevelopmental predictors of treatment response in schizophrenia and bipolar disorder

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction

Predictors of Antipsychotic Treatment Response in Patients with First Episode Schizophrenia, Schizoaffective, and Schizophreniform Disorders

How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis.

Reduced Brain Activity in the Right Putamen As an Early Predictor for Treatment Response in Drug-Naive, First-Episode Schizophrenia

Rates and Predictors of One-Year Antipsychotic Treatment Discontinuation in First-Episode Schizophrenia: Results from an Open-Label, Randomized, “real World” Clinical Trial

Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study

Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese

Early Treatment-Resistance in First Episode Psychosis